• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人脑皮质中L-[3H]尼古丁结合特性:阿尔茨海默病与正常情况的比较。

Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal.

作者信息

Flynn D D, Mash D C

出版信息

J Neurochem. 1986 Dec;47(6):1948-54. doi: 10.1111/j.1471-4159.1986.tb13113.x.

DOI:10.1111/j.1471-4159.1986.tb13113.x
PMID:3772387
Abstract

Putative nicotine receptors in the human cerebral cortex were characterized with L-[3H]nicotine, L-[3H]Nicotine binding was enhanced by the addition of Ca2+ and abolished in the presence of Na3EDTA. Association and dissociation of the ligand were rapid at 25 degrees C with t1/2 values of 2 and 3 min, respectively. Saturation binding analysis revealed an apparent single class of sites with a dissociation constant of 5.6 nM and a Hill coefficient of 1.05. There was no effect of postmortem interval on the density of binding sites assayed up to 24 h in rat frontoparietal cortex. Nicotine binding in human cortical samples was also unaltered by increasing sampling delay. In human cortical membranes, binding site density decreased with normal aging. Receptor affinity and concentration in samples of frontal cortex (Brodmann area 10) from patients with Alzheimer's disease were comparable to age-matched control values. Samples of infratemporal cortex (Brodmann area 38) from patients with Alzheimer's disease had a 50% reduction in the number of L-[3H]nicotine sites. Choline acetyltransferase activity was significantly decreased in both cortical areas. Enzyme activities in the temporal pole were reduced to 20% of control values. These data indicate that postsynaptic nicotine receptors are spared in the frontal cortex in Alzheimer's disease. In the infratemporal cortex, significant numbers of receptors remain despite the severe reduction in choline acetyltransferase activity. Replacement therapy directed at these sites may be warranted in Alzheimer's disease.

摘要

用L-[3H]尼古丁对人大脑皮质中的假定尼古丁受体进行了表征。添加Ca2+可增强L-[3H]尼古丁结合,而在Na3EDTA存在时结合被消除。在25℃时,配体的结合和解离迅速,半衰期分别为2分钟和3分钟。饱和结合分析显示存在一类表观位点,解离常数为5.6 nM,希尔系数为1.05。在大鼠额顶叶皮质中,直至24小时的尸检间隔对所检测的结合位点密度没有影响。增加采样延迟也不会改变人皮质样本中的尼古丁结合。在人皮质膜中,结合位点密度随正常衰老而降低。阿尔茨海默病患者额叶皮质(布罗德曼区10)样本中的受体亲和力和浓度与年龄匹配的对照值相当。阿尔茨海默病患者颞下皮质(布罗德曼区38)样本中L-[3H]尼古丁位点数量减少了50%。两个皮质区域的胆碱乙酰转移酶活性均显著降低。颞极的酶活性降至对照值的20%。这些数据表明,在阿尔茨海默病中,额叶皮质中的突触后尼古丁受体未受影响。在颞下皮质中,尽管胆碱乙酰转移酶活性严重降低,但仍有大量受体存在。针对这些位点的替代疗法可能适用于阿尔茨海默病。

相似文献

1
Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal.人脑皮质中L-[3H]尼古丁结合特性:阿尔茨海默病与正常情况的比较。
J Neurochem. 1986 Dec;47(6):1948-54. doi: 10.1111/j.1471-4159.1986.tb13113.x.
2
Nicotinic acetylcholine binding sites in Alzheimer's disease.阿尔茨海默病中的烟碱型乙酰胆碱结合位点
Brain Res. 1986 Apr 16;371(1):146-51. doi: 10.1016/0006-8993(86)90819-x.
3
Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex.阿尔茨海默病大脑皮质中的毒蕈碱型和烟碱型胆碱能结合位点。
Brain Res. 1987 Dec 8;436(1):62-8. doi: 10.1016/0006-8993(87)91556-3.
4
Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease.阿尔茨海默病颞叶皮质中[3H]尼古丁、[3H]金雀花碱和[3H]埃博霉素结合与囊泡乙酰胆碱转运位点关系的放射自显影比较。
Neuroscience. 1999;94(3):685-96. doi: 10.1016/s0306-4522(99)00295-x.
5
Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease.
J Neurochem. 1988 Jun;50(6):1914-23. doi: 10.1111/j.1471-4159.1988.tb02497.x.
6
Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease.
J Neurochem. 1993 Jan;60(1):197-203. doi: 10.1111/j.1471-4159.1993.tb05838.x.
7
Reductions in acetylcholine and nicotine binding in several degenerative diseases.几种退行性疾病中乙酰胆碱和尼古丁结合的减少。
Arch Neurol. 1988 Jul;45(7):722-4. doi: 10.1001/archneur.1988.00520310028012.
8
Effect of chronic nicotine treatment on nicotinic autoreceptor function and N-[3H]methylcarbamylcholine binding sites in the rat brain.慢性尼古丁处理对大鼠脑内烟碱型自身受体功能及N-[3H]甲基氨甲酰胆碱结合位点的影响。
J Neurochem. 1989 Feb;52(2):483-91. doi: 10.1111/j.1471-4159.1989.tb09146.x.
9
Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia.
Neurochem Res. 1989 Aug;14(8):745-50. doi: 10.1007/BF00964952.
10
Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains.阿尔茨海默病患者大脑额叶皮质中[3H]尼古丁和[3H]乙酰胆碱结合位点数量减少。
Neurosci Lett. 1986 Dec 3;72(1):115-9. doi: 10.1016/0304-3940(86)90629-4.

引用本文的文献

1
Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease.烟碱型乙酰胆碱受体与小胶质细胞作为阿尔茨海默病的治疗和成像靶点。
Molecules. 2022 Apr 27;27(9):2780. doi: 10.3390/molecules27092780.
2
Biological determinants impact the neurovascular toxicity of nicotine and tobacco smoke: A pharmacokinetic and pharmacodynamics perspective.生物学决定因素影响尼古丁和烟草烟雾的神经血管毒性:从药代动力学和药效动力学角度看。
Neurotoxicology. 2022 Mar;89:140-160. doi: 10.1016/j.neuro.2022.02.002. Epub 2022 Feb 9.
3
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.
痴呆症中的基底前脑胆碱能系统:脆弱性、弹性和抗性。
J Neurochem. 2021 Sep;158(6):1394-1411. doi: 10.1111/jnc.15471. Epub 2021 Aug 6.
4
(+)-[F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand-results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls.(+)-F 氟苯汀作为一种新型的α4β2 烟碱型乙酰胆碱受体 PET 配体——在伴有β-淀粉样蛋白 PET 证实的阿尔茨海默病和健康对照的患者中首次人体脑成像应用的结果。
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):731-746. doi: 10.1007/s00259-020-05029-w. Epub 2020 Sep 16.
5
Current radiotracers to image neurodegenerative diseases.用于成像神经退行性疾病的当前放射性示踪剂。
EJNMMI Radiopharm Chem. 2019 Jul 26;4(1):17. doi: 10.1186/s41181-019-0070-7.
6
Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease.帕金森病中胆碱能神经传递缺陷及其临床关联
NPJ Parkinsons Dis. 2016 Feb 18;2:16001. doi: 10.1038/npjparkd.2016.1. eCollection 2016.
7
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.吡贝地尔用于治疗帕金森病的运动和非运动症状
CNS Drugs. 2016 Aug;30(8):703-17. doi: 10.1007/s40263-016-0360-5.
8
Cholinergic imaging in dementia spectrum disorders.痴呆谱系障碍中的胆碱能成像
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1376-86. doi: 10.1007/s00259-016-3349-x. Epub 2016 Mar 16.
9
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.阿尔茨海默病和帕金森病神经精神症状的分子成像
Neurosci Biobehav Rev. 2015 Feb;49:157-70. doi: 10.1016/j.neubiorev.2014.11.010. Epub 2014 Nov 20.
10
Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice.可替宁阻止 Tg6799 小鼠阿尔茨海默病样病理和相关抑郁样行为的进展。
Front Aging Neurosci. 2014 Jul 23;6:162. doi: 10.3389/fnagi.2014.00162. eCollection 2014.